FI4080209T3 - Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi - Google Patents
Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi Download PDFInfo
- Publication number
- FI4080209T3 FI4080209T3 FIEP22173216.7T FI22173216T FI4080209T3 FI 4080209 T3 FI4080209 T3 FI 4080209T3 FI 22173216 T FI22173216 T FI 22173216T FI 4080209 T3 FI4080209 T3 FI 4080209T3
- Authority
- FI
- Finland
- Prior art keywords
- drugs
- immune
- mouse
- immune response
- inhibitors
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 13
- 229940124622 immune-modulator drug Drugs 0.000 title claims 2
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 229940079593 drug Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960001164 apremilast Drugs 0.000 claims 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229960000419 catumaxomab Drugs 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 229950006370 epacadostat Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486441P | 2017-04-17 | 2017-04-17 | |
| US201762521617P | 2017-06-19 | 2017-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4080209T3 true FI4080209T3 (fi) | 2024-06-24 |
Family
ID=62196678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22173216.7T FI4080209T3 (fi) | 2017-04-17 | 2018-04-17 | Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi |
| FIEP18725680.5T FI3612840T3 (fi) | 2017-04-17 | 2018-04-17 | Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18725680.5T FI3612840T3 (fi) | 2017-04-17 | 2018-04-17 | Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11959925B2 (es) |
| EP (3) | EP4361637A3 (es) |
| JP (3) | JP7179013B2 (es) |
| CN (1) | CN110770582A (es) |
| AU (2) | AU2018254420B2 (es) |
| CA (1) | CA3059923A1 (es) |
| DK (1) | DK4080209T3 (es) |
| ES (2) | ES2937797T3 (es) |
| FI (2) | FI4080209T3 (es) |
| WO (1) | WO2018195027A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4361637A3 (en) | 2017-04-17 | 2024-07-17 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| WO2020041174A1 (en) * | 2018-08-20 | 2020-02-27 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug |
| IL301634A (en) | 2020-09-24 | 2023-05-01 | Jackson Lab | Human mouse models for evaluating immune cell therapy |
| WO2023075539A1 (ko) * | 2021-10-29 | 2023-05-04 | 서울대학교 산학협력단 | 면역억제물질 예측용 유전자 집단의 선별방법 및 이를 이용한 면역억제능 평가방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105158B1 (en) * | 1992-11-16 | 2006-09-12 | The Corporation Of Mercer University | Methods of administering microencapsulated materials for immune modulated diseases |
| WO2011036308A1 (en) | 2009-09-28 | 2011-03-31 | Theramab Gmbh | Method for preclinical testing of immunomodulatory drugs |
| JP5874881B2 (ja) | 2009-10-06 | 2016-03-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝子改変されたマウスおよび移植方法 |
| EP2422618A1 (en) | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
| PT3375284T (pt) | 2011-02-15 | 2023-06-28 | Univ Yale | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| CN104160272A (zh) * | 2011-12-06 | 2014-11-19 | 麻省理工学院 | 利用人源化的小鼠来确定毒性 |
| CN103304669A (zh) * | 2012-03-12 | 2013-09-18 | 复旦大学 | 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途 |
| WO2014147216A1 (en) * | 2013-03-22 | 2014-09-25 | Imperial Innovations Ltd | In vitro method for assessing cytokine storm responses |
| AU2016284205B2 (en) | 2015-06-23 | 2021-12-02 | The Jackson Laboratory | Non-HLA matched humanized NSG mouse model with patient-derived xenograft |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| EP4361637A3 (en) | 2017-04-17 | 2024-07-17 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| CN110055223A (zh) | 2018-01-19 | 2019-07-26 | 北京百奥赛图基因生物技术有限公司 | 一种B2m基因改造的免疫缺陷动物的制备方法及其应用 |
| IL301634A (en) | 2020-09-24 | 2023-05-01 | Jackson Lab | Human mouse models for evaluating immune cell therapy |
-
2018
- 2018-04-17 EP EP24162485.7A patent/EP4361637A3/en active Pending
- 2018-04-17 EP EP18725680.5A patent/EP3612840B1/en active Active
- 2018-04-17 WO PCT/US2018/027887 patent/WO2018195027A1/en unknown
- 2018-04-17 US US16/605,753 patent/US11959925B2/en active Active
- 2018-04-17 FI FIEP22173216.7T patent/FI4080209T3/fi active
- 2018-04-17 ES ES18725680T patent/ES2937797T3/es active Active
- 2018-04-17 DK DK22173216.7T patent/DK4080209T3/da active
- 2018-04-17 CN CN201880037473.5A patent/CN110770582A/zh active Pending
- 2018-04-17 AU AU2018254420A patent/AU2018254420B2/en active Active
- 2018-04-17 JP JP2019556188A patent/JP7179013B2/ja active Active
- 2018-04-17 CA CA3059923A patent/CA3059923A1/en active Pending
- 2018-04-17 ES ES22173216T patent/ES2983677T3/es active Active
- 2018-04-17 FI FIEP18725680.5T patent/FI3612840T3/fi active
- 2018-04-17 EP EP22173216.7A patent/EP4080209B1/en active Active
-
2022
- 2022-11-15 JP JP2022182283A patent/JP7437482B2/ja active Active
-
2023
- 2023-06-26 US US18/341,029 patent/US11959926B2/en active Active
-
2024
- 2024-02-09 JP JP2024018523A patent/JP2024040343A/ja active Pending
- 2024-03-13 US US18/603,889 patent/US20240288445A1/en active Pending
- 2024-03-28 AU AU2024202008A patent/AU2024202008A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018195027A1 (en) | 2018-10-25 |
| JP2024040343A (ja) | 2024-03-25 |
| US11959926B2 (en) | 2024-04-16 |
| EP4080209A1 (en) | 2022-10-26 |
| AU2018254420A1 (en) | 2019-10-31 |
| EP4361637A2 (en) | 2024-05-01 |
| ES2937797T3 (es) | 2023-03-31 |
| AU2018254420B2 (en) | 2024-01-11 |
| EP4080209B1 (en) | 2024-04-03 |
| EP3612840B1 (en) | 2022-11-23 |
| US20210132080A1 (en) | 2021-05-06 |
| JP2020516902A (ja) | 2020-06-11 |
| EP3612840A1 (en) | 2020-02-26 |
| DK4080209T3 (en) | 2024-07-08 |
| CN110770582A (zh) | 2020-02-07 |
| US20230417763A1 (en) | 2023-12-28 |
| ES2983677T3 (es) | 2024-10-24 |
| US11959925B2 (en) | 2024-04-16 |
| AU2024202008A1 (en) | 2024-04-18 |
| EP4361637A3 (en) | 2024-07-17 |
| JP7179013B2 (ja) | 2022-11-28 |
| JP2023022092A (ja) | 2023-02-14 |
| FI3612840T3 (fi) | 2023-03-22 |
| JP7437482B2 (ja) | 2024-02-22 |
| US20220003781A9 (en) | 2022-01-06 |
| US20240288445A1 (en) | 2024-08-29 |
| CA3059923A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4080209T3 (fi) | Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi | |
| Schmid et al. | Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication | |
| Dwivedi et al. | Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions | |
| Stelekati et al. | Bystander chronic infection negatively impacts development of CD8+ T cell memory | |
| Klein et al. | Cytotoxic T lymphocytes produce immune interferon in response to antigen or mitogen. | |
| Nielsen et al. | Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals | |
| Teh et al. | Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection | |
| White et al. | Differential activation of CD 57‐defined natural killer cell subsets during recall responses to vaccine antigens | |
| Cambos et al. | Natural regulatory (CD4+ CD25+ FOXP+) T cells control the production of pro-inflammatory cytokines during Plasmodium chabaudi adami infection and do not contribute to immune evasion | |
| JP2023022092A5 (es) | ||
| Zhu et al. | TLR3 signaling in macrophages is indispensable for the protective immunity of invariant natural killer T cells against enterovirus 71 infection | |
| Alhakeem et al. | Role of B cell receptor signaling in IL‐10 production by normal and malignant B‐1 cells | |
| Mourglia-Ettlin et al. | Susceptibility and resistance to Echinococcus granulosus infection: Associations between mouse strains and early peritoneal immune responses | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| Urban et al. | Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses | |
| Zhou et al. | Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation | |
| Arnold et al. | Immune reconstitution following TCRαβ/CD19-depleted hematopoietic cell transplantation for hematologic malignancy in pediatric patients | |
| Murray et al. | CD40 is required for protective immunity against liver stage Plasmodium infection | |
| Xu et al. | Effects of vaccination with the C-strain vaccine on immune cells and cytokines of pigs against classical swine fever virus | |
| Dos Reis et al. | β-glucan mimics tissue damage signaling and generates a trade-off between head kidney and spleen to activate acquired immunity in vaccinated tilapia (Oreochromis niloticus) | |
| RU2011146149A (ru) | Способ прогнозирования преждевременных родов и внутриутробного инфицирования плода | |
| Vesosky et al. | CD8 T Cells in old mice contribute to the innate immune response to Mycobacterium tuberculosis via interleukin-12p70-dependent and antigen-independent production of gamma interferon | |
| Pawar et al. | Unlocking therapeutic potential: Integration of drug repurposing and immunotherapy for various disease targeting | |
| Stepanova et al. | Interleukin-17 producing cells in swine induced by microbiota during the early postnatal period-a brief research report | |
| Nolte et al. | Assessment and characterization of the cytolytic T lymphocyte response against Epstein–Barr virus in patients with non-Hodgkin’s lymphoma after autologous peripheral blood stem cell transplantation |